Genscience Unveils Shanghai Innovative Drug Production Base with Grand Opening Ceremony
Author: Century 3 Update: 2023-06-16
On June 16, 2023, Genscience held a celebration marking the completion and commissioning of its innovative drug production base in Shanghai. The project, with a total investment of 500 million RMB, is located in the Zhangjiang Innovative Medicine Industrial Park and is set to bring more medical choices to over one million patients worldwide. Century 3 has provided conceptual design, basic design, detailed design construction management, validation to this project.
Started in April 2019, the Zhangjiang plant covers an area of 3.1 square kilometers and is equipped with a 2x500L and a 2x2000L scale raw liquid production line, a sterile freeze-drying preparation production line. The state-of-the-art plant is capable of producing up to 10 billion units of various long-acting (ultra-long-acting) recombinant coagulation factors annually. Genscience has already entered different stages of industrialization and clinical application with four long-acting (ultra-long-acting) recombinant coagulation factor products.
Century 3, with a proven-track record of delivering professional engineering and construction management services to pharmaceutical client, was proudly to be selected as the service provider for Genscience’s Shanghai project. The successful completion of Genscience’s Zhangjiang production base is a testament to the Century 3’s expertise and capabilities in the pharmaceutical industry and demonstrates its commitment to helping its clients achieve success and realize their goals.